Purpose: At the height of the COVID-19 pandemic, our institution instituted a Safe Tracheostomy Aftercare Taskforce (STAT) team to care for the influx of patients undergoing tracheostomies. This review was undertaken to understand this team's impact on outcomes of tracheostomy care.
Methods: We compared retrospective data collected from patients undergoing tracheostomies at our institution from February to June 2019, prior to creation of the STAT team, to prospectively collected data from tracheostomies performed from February to June 2020, while the STAT team was in place and performed statistical analysis on outcomes of care such as decannulation prior to discharge, timely tube change, and post-discharge follow-up.
Results: We found that the STAT team significantly increased rate of decannulation prior to discharge (P < 0.0005), performance of timely trach tube change when indicated (P < 0.05), and rates of follow-up for tracheostomy patients after discharge from the hospital (P < 0.0005).
Conclusion: The positive impact of the STAT team on outcomes of patient care such as decannulation prior to discharge, timely tube change, and post-discharge follow-up makes a strong case for its continuation even in non-pandemic times.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443539 | PMC |
| http://dx.doi.org/10.1016/j.amjoto.2021.103240 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Study protocol for a Prospective Observational study of Safety Threats and Adverse events in Trauma (PrO-STAT): a pilot study at a level-1 trauma centre in Canada.
BMJ Open
January 2025
Department of Emergency Medicine, St Michael's Hospital, Toronto, Ontario, Canada.
Introduction: Traumatic injuries are a significant public health concern globally, resulting in substantial mortality, hospitalisation and healthcare burden. Despite the establishment of specialised trauma centres, there remains considerable variability in trauma-care practices and outcomes, particularly in the initial phase of trauma resuscitation in the trauma bay. This stage is prone to preventable errors leading to adverse events (AEs) that can impact patient outcomes.
View Article and Find Full Text PDFIntegrative analysis of ASXL family genes reveals ASXL2 as an immunoregulatory molecule in head and neck squamous cell carcinoma.
Sci Rep
December 2024
Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan, People's Republic of China.
Despite the progress in conventional treatments for head and neck squamous cell carcinoma (HNSCC), the 5-year survival rate remains below 70%. Enhancing immunotherapy outcomes through personalized treatment strategies, particularly by identifying immune-related biomarkers, is critical. The ASXL family are associated with malignancies, but their relationship with HNSCC has not been elucidated.
View Article and Find Full Text PDFSafety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.
EBioMedicine
December 2024
Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Section for Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway. Electronic address:
Background: The Bari-SolidAct randomized controlled trial compared baricitinib with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher incidence of serious adverse events (SAEs) among SARS-CoV-2-vaccinated participants who had received baricitinib. This sub-study aimed to investigate whether vaccination influences the safety profile of baricitinib in patients with severe COVID-19.
View Article and Find Full Text PDFInvestigating the impact of data monitoring committee recommendations on the probability of trial success.
J Biopharm Stat
December 2024
Chiesi Farmaceutici, Statistical Methodology, Parma, Italy.
Determining the probability of success of a clinical trial using a prior distribution on the treatment effect can significantly enhance decision-making by the sponsor. In a group sequential design, the probability of success calculated at the design stage can be updated to incorporate the information disclosed by the Data Monitoring Committee (DMC), usually consisting in a simple statement that advises to continue or to stop the trial, either for efficacy or futility, following pre-specified rules defined in the protocol. We define the "probability of success post interim" as the probability of success conditioned on the assumption that the DMC recommends continuing the trial after an interim analysis.
View Article and Find Full Text PDFSiwu decoction mitigates radiation-induced immune senescence by attenuating hematopoietic damage.
Chin Med
December 2024
Department of Pharmacology and Toxicology , Beijing Institute of Radiation Medicine, Beijing, China.
Background: To investigate the long term effects of ionizing radiation (IR) on hematopoietic stem/progenitor cells (HSPCs), immune tissues and cells, and the effects of Siwu decoction (SWD) on immune senescence mice.
Methods: C57BL/6 J mice were exposed to 6.0 Gy Co γ irradiation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!